Skip to main content

Liver Cancer Clinical Trials

Review the liver cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 162

Immunotherapy with or without Radiation Therapy for the Treatment of Patients with Advanced Unresectable Intrahepatic Cholangiocarcinoma, a HYPERION CCA Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Sacituzumab Govitecan for the Treatment for Patients with Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma, Gallbladder or Biliary Tract Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Cell Therapy (Tumor Infiltrating Lymphocytes) and Aldesleukin in Treating Patients with Locally Advanced, Recurrent, Refractory, or Metastatic Biliary Tract Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Ligufalimab and Cadonilimab for the Treatment of Advanced Hepatobiliary Cancers
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
Status: Active
Location: 2 locations
Immunotherapy (Pembrolizumab or Nivolumab) with Metformin or Rosiglitazone for the Treatment of Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Nivolumab, Fluorouracil, and PegInterferon-Alpha2a for the Treatment of Unresectable Fibrolamellar Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Valemetostat Tosylate with Atezolizumab and Bevacizumab for the Treatment of Locally Advanced, Unresectable or Metastatic Hepatocellular Carcinoma
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Pemigatinib and Atezolizumab With or Without Bevacizumab for Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cabozantinib and Durvalumab with or without Tremelimumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Status: Active
Location: 2 locations
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Genetically Engineered Cells (SC-CAR.GPC3xIL15.21 T Cells) for the Treatment of Pediatric and Adolescent/Young Adult Patients with GPC3-Positive Solid Cancers, IMPACT Trial
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
NP-101 before Y-90 Radioembolization for the Treatment of Unresectable Hepatocellular Carcinoma
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Drug Combination Therapy (Sorafenib, Sonidegib, and Irinotecan) for the Treatment of Patients with Advanced Hepatocellular Carcinoma, AD HOC Trial
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Y-90 SIRT and SBRT for the Treatment of Unresectable Liver Cancer
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
DRP-104 in Combination with Durvalumab for the Treatment of Patients with Metastatic or Unresectable Fibrolamellar Hepatocellular Carcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Cryoablation and Hepatic Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab for the Treatment of Locally Advanced or Metastatic and/or Unresectable Liver cancer
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination with Gemcitabine, Cisplatin and Durvalumab for the Treatment of Biliary Tract Cancer Patients with Peritoneal Metastases
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California